

Marc Buyse

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/10738596/marc-buyse-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

164
papers

21,863
citations

65
h-index

147
g-index

170
ext. papers

24,721
ext. citations

6.5
avg, IF

6.2
L-index

#	Paper	IF	Citations
164	Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy.. <i>Oncologist</i> , 2022 , 27, 266-271	5.7	0
163	Impact of follow-up on generalized pairwise comparisons for estimating the irinotecan benefit in advanced/metastatic gastric cancer. <i>Contemporary Clinical Trials</i> , 2021 , 105, 106400	2.3	
162	Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study. <i>Statistics in Medicine</i> , 2021 , 40, 553-565	2.3	3
161	Unbiasedness and efficiency of non-parametric and UMVUE estimators of the probabilistic index and related statistics. <i>Statistical Methods in Medical Research</i> , 2021 , 30, 747-768	2.3	4
160	A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons. <i>Biometrical Journal</i> , 2021 , 63, 272-288	1.5	2
159	Generalized Pairwise Comparisons for Prioritized Outcomes 2021 , 1-25		1
158	Correcting the bias of the net benefit estimator due to right-censored observations. <i>Biometrical Journal</i> , 2021 , 63, 893-906	1.5	1
157	The Net Benefit of a treatment should take the correlation between benefits and harms into account. <i>Journal of Clinical Epidemiology</i> , 2021 , 137, 148-158	5.7	1
156	Detection of Fraud in a Clinical Trial Using Unsupervised Statistical Monitoring. <i>Therapeutic Innovation and Regulatory Science</i> , 2021 , 1	1.2	1
155	Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3032-3041	2.2	13
154	Assessing Treatment Benefit in Immuno-oncology. <i>Statistics in Biosciences</i> , 2020 , 12, 83-103	1.5	4
153	Outcome measures in multimodal rectal cancer trials. <i>Lancet Oncology, The</i> , 2020 , 21, e252-e264	21.7	24
152	Fraud in Clinical Trials 2020 , 1-20		
151	Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer. <i>Cancers</i> , 2020 , 12,	6.6	1
150	Central statistical monitoring of investigator-led clinical trials in oncology. <i>International Journal of Clinical Oncology</i> , 2020 , 25, 1207-1214	4.2	3
149	Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints. <i>Current Opinion in Oncology</i> , 2020 , 32, 384-390	4.2	2
148	Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. <i>JAMA Network Open</i> , 2019 , 2, e1911750	10.4	1

147	Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. <i>Lancet Oncology, The</i> , 2019 , 20, 361-370	21.7	26
146	What Does Metastasis-Free Survival Actually Mean?. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1679-1680	2.2	1
145	A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz002	4.6	18
144	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019 , 21, 39	8.3	11
143	Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 1186-1191	9.7	6
142	The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2019 , 48, 275-280	2.6	10
141	Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring. <i>Clinical Trials</i> , 2019 , 16, 512-522	2.2	5
140	Generalized Pairwise Comparisons 2019 , 1-9		1
139	Multiple Prioritized Outcomes 2019 , 1-9		1
138	A Poisson approach to the validation of failure time surrogate endpoints in individual patient data meta-analyses. <i>Statistical Methods in Medical Research</i> , 2019 , 28, 170-183	2.3	11
137	Meta-analysis of randomized clinical trials in the era of individual patient data sharing. <i>International Journal of Clinical Oncology</i> , 2018 , 23, 403-409	4.2	9
136	An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring. <i>Statistical Methods in Medical Research</i> , 2018 , 27, 1230-1239	2.3	31
135	Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2018 , 110,	9.7	49
134	Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better?. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 232-240	9.7	22
133	Precision medicine needs randomized clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 317-323	19.4	45
132	Improving public health by improving clinical trial guidelines and their application. <i>European Heart Journal</i> , 2017 , 38, 1632-1637	9.5	15
131	Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors. <i>Drugs</i> , 2017 , 77, 713-719	12.1	22
130	Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. <i>Value in Health</i> , 2017 , 20, 487-495	3.3	61

129	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3097-3104	2.2	215
128	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 1688-1700	21.7	328
127	The impact of data errors on the outcome of randomized clinical trials. <i>Clinical Trials</i> , 2017 , 14, 499-506	2.2	12
126	HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 228-238	6.1	25
125	Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial. <i>Gastric Cancer</i> , 2016 , 19, 24-30	7.6	14
124	HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3518-3528	2.2	92
123	Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. <i>Nature Reviews Drug Discovery</i> , 2016 , 15, 516	64.1	15
122	Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply. <i>Lancet Oncology, The</i> , 2016 , 17, e176-7	21.7	12
121	Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. <i>Biometrical Journal</i> , 2016 , 58, 104-32	1.5	54
120	Fraud in clinical trials: complex problem, simple solutions?. <i>International Journal of Clinical Oncology</i> , 2016 , 21, 13-4	4.2	2
119	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 367-377	21.7	339
118	Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 412-51	2.2	361
117	An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. <i>Oncotarget</i> , 2016 , 7, 82953-82960	3.3	19
116	Fraud in Clinical Trials 2016 , 1-13		2
115	Data fraud in clinical trials. <i>Clinical Investigation</i> , 2015 , 5, 161-173		60
114	Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. <i>Journal of Clinical Epidemiology</i> , 2015 , 68, 833-42	5.7	37
113	Common pitfalls in statistical analysis: "P" values, statistical significance and confidence intervals. <i>Perspectives in Clinical Research</i> , 2015 , 6, 116-7	1.4	13
112	Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1348-55	2.2	295

111	Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. <i>Journal of Clinical Oncology</i> , 2015 , 33, 22-8	2.2	69
110	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv261	9.7	35
109	Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 141-8	2.2	90
108	Common pitfalls in statistical analysis: Clinical versus statistical significance. <i>Perspectives in Clinical Research</i> , 2015 , 6, 169-70	1.4	91
107	Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. <i>Lancet Oncology</i> , 2014 , 15, 886-93	21.7	84
106	Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. <i>International Journal of Technology Assessment in Health Care</i> , 2014 , 30, 312-24	1.8	49
105	Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 99-108	4.4	70
104	Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 1205-12	3.5	52
103	Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1667-70	9.7	58
102	Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. <i>European Journal of Cancer</i> , 2013 , 49, 1565-77	7.5	119
101	Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1600-7	9.7	102
100	Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. <i>BMJ Open</i> , 2013 , 3,	3	34
99	Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study. <i>BMJ</i> , 2013 , 346, f457	5.9	90
98	Omics-based clinical trial designs. <i>Current Opinion in Oncology</i> , 2013 , 25, 289-95	4.2	13
97	Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3764-75	2.2	155
96	Surrogate end points: when should they be used?. <i>Clinical Investigation</i> , 2013 , 3, 1147-1155		
95	Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer. <i>PLoS ONE</i> , 2013 , 8, e66848	3.7	13
94	Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. <i>Breast Cancer Research</i> , 2012 , 14, R70	8.3	47

93	Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time. <i>Biometrics</i> , 2012 , 68, 248-57	1.8	12
92	A statistical approach to central monitoring of data quality in clinical trials. <i>Clinical Trials</i> , 2012 , 9, 705-13	2.2	62
91	Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects. <i>Acta Oncologica</i> , 2012 , 51, 890-6	3.2	21
90	Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1750-4	2.2	57
89	Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. <i>Clinical Cancer Research</i> , 2012 , 18, 3478-86	12.9	89
88	The ARCAD clinical trials program: an update and invitation. <i>Oncologist</i> , 2012 , 17, 188-91	5.7	4
87	Adjuvant trastuzumab in HER2-positive breast cancer. <i>New England Journal of Medicine</i> , 2011 , 365, 1273-82	5.9	1788
86	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , 2011 , 12, 1134-42	21.7	141
85	Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia. <i>Trials</i> , 2011 , 12, 86	2.8	7
84	Integrating biomarkers in clinical trials. <i>Expert Review of Molecular Diagnostics</i> , 2011 , 11, 171-82	3.8	104
83	Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials. <i>Computational Statistics and Data Analysis</i> , 2011 , 55, 2748-2757	1.6	21
82	Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. <i>Haematologica</i> , 2011 , 96, 1106-12	6.6	31
81	Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4199-204	2.2	45
80	Multifactorial approach to predicting resistance to anthracyclines. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1578-86	2.2	143
79	Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 859-67	2.2	158
78	Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3877-84	2.2	116
77	Survival is not a good outcome for randomized trials with effective subsequent therapies. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4719-20; author reply 4720-1	2.2	28
76	Reply to R. Simon. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2941-2944	2.2	

75	Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 303, 1729-37	27.4	586
74	Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1958-62	2.2	129
73	Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. <i>Journal of Clinical Oncology</i> , 2010 , 28, 460-5	2.2	49
72	Biomarkers and surrogate end points--the challenge of statistical validation. <i>Nature Reviews Clinical Oncology</i> , 2010 , 7, 309-17	19.4	240
71	Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1). <i>Clinical Colorectal Cancer</i> , 2010 , 9, E5-10	3.8	2
70	E23. Statistical issues in the validation of biomarkers and surrogate endpoints. <i>European Journal of Cancer, Supplement</i> , 2010 , 8, 48-49	1.6	
69	Generalized pairwise comparisons of prioritized outcomes in the two-sample problem. <i>Statistics in Medicine</i> , 2010 , 29, 3245-57	2.3	98
68	Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. <i>Journal of Clinical Oncology</i> , 2009 , 27, 872-7	2.2	400
67	Contributions of meta-analyses based on individual patient data to therapeutic progress in colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2009 , 14, 95-101	4.2	8
66	Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. <i>Lancet Oncology, The</i> , 2009 , 10, 341-50	21.7	118
65	Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials. <i>Cancer Journal (Sudbury, Mass)</i> , 2009 , 15, 421-5	2.2	28
64	Comparison of prognostic gene expression signatures for breast cancer. <i>BMC Genomics</i> , 2008 , 9, 394	4.5	110
63	Ensuring trial validity by data quality assurance and diversification of monitoring methods. <i>Clinical Trials</i> , 2008 , 5, 49-55	2.2	104
62	Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. <i>Clinical Cancer Research</i> , 2008 , 14, 5158-65	12.9	641
61	Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1980-6	2.2	173
60	Reformulating the hazard ratio to enhance communication with clinical investigators. <i>Clinical Trials</i> , 2008 , 5, 641-2	2.2	23
59	Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1987-92	2.3	273
58	Individual- and trial-level surrogacy in colorectal cancer. <i>Statistical Methods in Medical Research</i> , 2008 , 17, 467-75	2.3	48

57	Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 121-33	9.7	123
56	Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments. <i>Current Opinion in Oncology</i> , 2008 , 20, 466-71	4.2	19
55	Exploring and validating surrogate endpoints in colorectal cancer. <i>Lifetime Data Analysis</i> , 2008 , 14, 54-64	4.3	21
54	Progression-free survival is a surrogate for survival in advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5218-24	2.2	278
53	Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 998-1003	9.7	240
52	Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1239-46	2.2	650
51	End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4569-74	2.2	183
50	End points in advanced colon cancer clinical trials: a review and proposal. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3572-5	2.2	61
49	Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3732-8	2.2	120
48	Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. <i>Clinical Cancer Research</i> , 2007 , 13, 3207-14	12.9	759
47	Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5673-4; author reply 5674	2.2	10
46	Towards validation of statistically reliable biomarkers. <i>European Journal of Cancer, Supplement</i> , 2007 , 5, 89-95	1.6	14
45	Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3224-9	2.2	107
44	Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. <i>Journal of Rheumatology</i> , 2007 , 34, 607-15	4.1	68
43	Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 1183-92	9.7	976
42	Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, 540-51		202
41	OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. <i>Journal of Clinical Oncology</i> , 2006 , 24, 394-400	2.2	633
40	Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 262-72	9.7	1485

39	Current issues in adjuvant treatment of stage II colon cancer. <i>Annals of Surgical Oncology</i> , 2006 , 13, 887-98		81
38	A unifying approach for surrogate marker validation based on Prentice [®] criteria. <i>Statistics in Medicine</i> , 2006 , 25, 205-21	2.3	43
37	Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. <i>Pharmaceutical Statistics</i> , 2006 , 5, 173-86	1	126
36	Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8664-70	2.2	509
35	Fraud in Clinical Trials 2005 ,		2
34	Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. <i>Journal of Clinical Oncology</i> , 2004 , 22, 484-92	2.2	115
33	Meta-analyses based on abstracted data: a step in the right direction, but only a first step. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3839-41	2.2	76
32	The validation of surrogate end points by using data from randomized clinical trials: a case-study in advanced colorectal cancer. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2004 , 167, 103-124	2.1	57
31	FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. <i>Journal of Clinical Oncology</i> , 2004 , 22, 229-37	2.2	2358
30	Challenges in breast cancer clinical trial design in the postgenomic era. <i>Current Opinion in Oncology</i> , 2004 , 16, 536-41	4.2	13
29	A perspective on surrogate endpoints in controlled clinical trials. <i>Statistical Methods in Medical Research</i> , 2004 , 13, 177-206	2.3	47
28	Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2896-903	2.2	215
27	Progress in the medical treatment of advanced colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 711-6	3.5	2
26	Cornerstones of a well-designed phase III trial. <i>European Journal of Cancer, Supplement</i> , 2003 , 1, 67-75	1.6	3
25	Simplified hierarchical linear models for the evaluation of surrogate endpoints. <i>Journal of Statistical Computation and Simulation</i> , 2003 , 73, 643-658	0.9	34
24	Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2045-7	2.2	59
23	Validation of Biomarkers as Surrogates for Clinical Endpoints. <i>Drugs and the Pharmaceutical Sciences</i> , 2003 ,		3
22	Statistical challenges in the evaluation of surrogate endpoints in randomized trials. <i>Contemporary Clinical Trials</i> , 2002 , 23, 607-25		95

21	Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes. <i>Biometrical Journal</i> , 2002 , 44, 921-935	1.5	40
20	Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2002 , 2, 417-25	3.5	3
19	Validation of surrogate end points in multiple randomized clinical trials with failure time end points. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2001 , 50, 405-422	1.5	137
18	Should DukesRB patients receive adjuvant therapy? A statistical perspective. <i>Seminars in Oncology</i> , 2001 , 28, 20-4	5.5	65
17	Re: A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. <i>Journal of the National Cancer Institute</i> , 2001 , 93, 399-401	9.7	7
16	Should DukesRB patients receive adjuvant therapy? A statistical perspective. <i>Seminars in Oncology</i> , 2001 , 28, 20-24	5.5	13
15	Fraud in medical research: an international survey of biostatisticians. ISCB Subcommittee on Fraud. <i>Contemporary Clinical Trials</i> , 2000 , 21, 415-27		65
14	Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. <i>Lancet, The</i> , 2000 , 356, 373-8	4.0	35.0
13	Clinical Research after Drug Approval: What is Needed and What is Not. <i>Drug Information Journal</i> , 1999 , 33, 627-634		5
12	The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. <i>Statistics in Medicine</i> , 1999 , 18, 3435-51	2.3	109
11	Criteria for the Validation of Surrogate Endpoints in Randomized Experiments. <i>Biometrics</i> , 1998 , 54, 1014-8		293
10	The trials of Dr. Bernard Fisher: a European perspective on an American episode. <i>Contemporary Clinical Trials</i> , 1997 , 18, 1-13		21
9	On the relationship between response to treatment and survival time. <i>Statistics in Medicine</i> , 1996 , 15, 2797-812	2.3	87
8	The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. <i>New England Journal of Medicine</i> , 1995 , 332, 629-34	59.2	612
7	Interim analyses, stopping rules and data monitoring in clinical trials in Europe. <i>Statistics in Medicine</i> , 1993 , 12, 509-20	2.3	23
6	Adjuvant Therapy of Colorectal Cancer. <i>JAMA - Journal of the American Medical Association</i> , 1988 , 259, 3571	27.4	210
5	Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC). <i>Annals of Surgery</i> , 1988 , 208, 606-14	7.8	509
4	Counting and sampling errors: (mis)interpretation of data from tritiated thymidine labelled human tumors. <i>European Journal of Cancer & Clinical Oncology</i> , 1987 , 23, 895-6		

3	Issues of efficiency in combining proportions of deaths from several clinical trials. <i>Statistics in Medicine</i> , 1987 , 6, 565-76	2.3	16
2	Interim analysis of a phase III study on preoperative radiation therapy in resectable rectal carcinoma. Trial of the Gastrointestinal Tract Cancer Cooperative Group of the European Organization for Research on Treatment of Cancer (EORTC). <i>Cancer</i> , 1985 , 55, 2373-9	6.4	85
1	Cell kinetic indicators of premalignant stages of colorectal cancer. <i>Cancer</i> , 1985 , 56, 124-9	6.4	90